FIGO staging of endometrial cancer: 2023
Many advances in the understanding of the pathologic and molecular features of endometrial cancer have occurred since the FIGO staging was last updated in 2009. Substantially more outcome and biological behavior data are now available regarding the several histological types. Molecular and genetic f...
Uloženo v:
| Vydáno v: | Journal of gynecologic oncology Ročník 34; číslo 5; s. e85 - 18 |
|---|---|
| Hlavní autoři: | , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
Korea (South)
Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology; Japan Society of Gynecologic Oncology
01.09.2023
대한부인종양학회 |
| Témata: | |
| ISSN: | 2005-0380, 2005-0399, 2005-0399 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Many advances in the understanding of the pathologic and molecular features of endometrial cancer have occurred since the FIGO staging was last updated in 2009. Substantially more outcome and biological behavior data are now available regarding the several histological types. Molecular and genetic findings have accelerated since the publication of The Cancer Genome Atlas (TCGA) data and provide improved clarity on the diverse biological nature of this collection of endometrial cancers and their differing prognostic outcomes. The goals of the new staging system are to better define these prognostic groups and create substages that indicate more appropriate surgical, radiation, and systemic therapies.
The FIGO Women's Cancer Committee appointed a Subcommittee on Endometrial Cancer Staging in October 2021, represented by the authors. Since then, the committee members have met frequently and reviewed new and established evidence on the treatment, prognosis, and survival of endometrial cancer. Based on these data, opportunities for improvements in the categorization and stratification of these factors were identified in each of the four stages. Data and analyses from the molecular and histological classifications performed and published in the recently developed ESGO/ESTRO/ESP guidelines were used as a template for adding the new subclassifications to the proposed molecular and histological staging system.
Based on the existing evidence, the substages were defined as follows:
non-aggressive histological type of endometrial carcinoma limited to a polyp or confined to the endometrium; (IA2) non-aggressive histological types of endometrium involving less than 50% of the myometrium with no or focal lymphovascular space invasion (LVSI) as defined by WHO criteria; (IA3) low-grade endometrioid carcinomas limited to the uterus with simultaneous low-grade endometrioid ovarian involvement; (IB) non-aggressive histological types involving 50% or more of the myometrium with no LVSI or focal LVSI; (IC) aggressive histological types, i.e. serous, high-grade endometrioid, clear cell, carcinosarcomas, undifferentiated, mixed, and other unusual types without any myometrial invasion.
non-aggressive histological types that infiltrate the cervical stroma; (IIB) non-aggressive histological types that have substantial LVSI; or (IIC) aggressive histological types with any myometrial invasion.
differentiating between adnexal versus uterine serosa infiltration; (IIIB) infiltration of vagina/parametria and pelvic peritoneal metastasis; and (IIIC) refinements for lymph node metastasis to pelvic and para-aortic lymph nodes, including micrometastasis and macrometastasis.
locally advanced disease infiltrating the bladder or rectal mucosa; (IVB) extrapelvic peritoneal metastasis; and (IVC) distant metastasis. The performance of complete molecular classification (
, MMRd, NSMP, p53abn) is encouraged in all endometrial cancers. If the molecular subtype is known, this is recorded in the FIGO stage by the addition of "m" for molecular classification, and a subscript indicating the specific molecular subtype. When molecular classification reveals p53abn or
status in Stages I and II, this results in upstaging or downstaging of the disease (IICm
or IAm
).
The updated 2023 staging of endometrial cancer includes the various histological types, tumor patterns, and molecular classification to better reflect the improved understanding of the complex nature of the several types of endometrial carcinoma and their underlying biologic behavior. The changes incorporated in the 2023 staging system should provide a more evidence-based context for treatment recommendations and for the more refined future collection of outcome and survival data. |
|---|---|
| AbstractList | Introduction: Many advances in the understanding of the pathologic and molecular features of endometrial cancer have occurred since the FIGO staging was last updated in 2009. Substantially more outcome and biological behavior data are now available regarding the several histological types. Molecular and genetic findings have accelerated since the publication of The Cancer Genome Atlas (TCGA) data and provide improved clarity on the diverse biological nature of this collection of endometrial cancers and their differing prognostic outcomes. The goals of the new staging system are to better define these prognostic groups and create substages that indicate more appropriate surgical, radiation, and systemic therapies.
Methods: The FIGO Women's Cancer Committee appointed a Subcommittee on Endometrial Cancer Staging in October 2021, represented by the authors. Since then, the committee members have met frequently and reviewed new and established evidence on the treatment, prognosis, and survival of endometrial cancer. Based on these data, opportunities for improvements in the categorization and stratification of these factors were identified in each of the four stages. Data and analyses from the molecular and histological classifications performed and published in the recently developed ESGO/ESTRO/ESP guidelines were used as a template for adding the new subclassifications to the proposed molecular and histological staging system.
Results: Based on the existing evidence, the substages were defined as follows: S tage I (IA1): non-aggressive histological type of endometrial carcinoma limited to a polyp or confined to the endometrium; (IA2) non-aggressive histological types of endometrium involving less than 50% of the myometrium with no or focal lymphovascular space invasion (LVSI) as defined by WHO criteria; (IA3) low-grade endometrioid carcinomas limited to the uterus with simultaneous low-grade endometrioid ovarian involvement; (IB) non-aggressive histological types involving 50% or more of the myometrium with no LVSI or focal LVSI; (IC) aggressive histological types, i.e. serous, high-grade endometrioid, clear cell, carcinosarcomas, undifferentiated, mixed, and other unusual types without any myometrial invasion.
S tage II (IIA): non-aggressive histological types that infiltrate the cervical stroma; (IIB) non-aggressive histological types that have substantial LVSI; or (IIC) aggressive histological types with any myometrial invasion.
S tage III (IIIA): differentiating between adnexal versus uterine serosa infiltration; (IIIB) infiltration of vagina/parametria and pelvic peritoneal metastasis; and (IIIC) refinements for lymph node metastasis to pelvic and para-aortic lymph nodes, including micrometastasis and macrometastasis.
S tage IV (IVA): locally advanced disease infiltrating the bladder or rectal mucosa; (IVB) extrapelvic peritoneal metastasis; and (IVC) distant metastasis. The performance of complete molecular classification (POLEmut, MMRd, NSMP, p53abn) is encouraged in all endometrial cancers. If the molecular subtype is known, this is recorded in the FIGO stage by the addition of “m” for molecular classification, and a subscript indicating the specific molecular subtype. When molecular classification reveals p53abn or POLEmut status in Stages I and II, this results in upstaging or downstaging of the disease (IICmp53abn or IAmPOLEmut).
Summary: The updated 2023 staging of endometrial cancer includes the various histological types, tumor patterns, and molecular classification to better reflect the improved understanding of the complex nature of the several types of endometrial carcinoma and their underlying biologic behavior. The changes incorporated in the 2023 staging system should provide a more evidence-based context for treatment recommendations and for the more refined future collection of outcome and survival data. KCI Citation Count: 0 Many advances in the understanding of the pathologic and molecular features of endometrial cancer have occurred since the FIGO staging was last updated in 2009. Substantially more outcome and biological behavior data are now available regarding the several histological types. Molecular and genetic findings have accelerated since the publication of The Cancer Genome Atlas (TCGA) data and provide improved clarity on the diverse biological nature of this collection of endometrial cancers and their differing prognostic outcomes. The goals of the new staging system are to better define these prognostic groups and create substages that indicate more appropriate surgical, radiation, and systemic therapies. The FIGO Women's Cancer Committee appointed a Subcommittee on Endometrial Cancer Staging in October 2021, represented by the authors. Since then, the committee members have met frequently and reviewed new and established evidence on the treatment, prognosis, and survival of endometrial cancer. Based on these data, opportunities for improvements in the categorization and stratification of these factors were identified in each of the four stages. Data and analyses from the molecular and histological classifications performed and published in the recently developed ESGO/ESTRO/ESP guidelines were used as a template for adding the new subclassifications to the proposed molecular and histological staging system. Based on the existing evidence, the substages were defined as follows: non-aggressive histological type of endometrial carcinoma limited to a polyp or confined to the endometrium; (IA2) non-aggressive histological types of endometrium involving less than 50% of the myometrium with no or focal lymphovascular space invasion (LVSI) as defined by WHO criteria; (IA3) low-grade endometrioid carcinomas limited to the uterus with simultaneous low-grade endometrioid ovarian involvement; (IB) non-aggressive histological types involving 50% or more of the myometrium with no LVSI or focal LVSI; (IC) aggressive histological types, i.e. serous, high-grade endometrioid, clear cell, carcinosarcomas, undifferentiated, mixed, and other unusual types without any myometrial invasion. non-aggressive histological types that infiltrate the cervical stroma; (IIB) non-aggressive histological types that have substantial LVSI; or (IIC) aggressive histological types with any myometrial invasion. differentiating between adnexal versus uterine serosa infiltration; (IIIB) infiltration of vagina/parametria and pelvic peritoneal metastasis; and (IIIC) refinements for lymph node metastasis to pelvic and para-aortic lymph nodes, including micrometastasis and macrometastasis. locally advanced disease infiltrating the bladder or rectal mucosa; (IVB) extrapelvic peritoneal metastasis; and (IVC) distant metastasis. The performance of complete molecular classification ( , MMRd, NSMP, p53abn) is encouraged in all endometrial cancers. If the molecular subtype is known, this is recorded in the FIGO stage by the addition of "m" for molecular classification, and a subscript indicating the specific molecular subtype. When molecular classification reveals p53abn or status in Stages I and II, this results in upstaging or downstaging of the disease (IICm or IAm ). The updated 2023 staging of endometrial cancer includes the various histological types, tumor patterns, and molecular classification to better reflect the improved understanding of the complex nature of the several types of endometrial carcinoma and their underlying biologic behavior. The changes incorporated in the 2023 staging system should provide a more evidence-based context for treatment recommendations and for the more refined future collection of outcome and survival data. Many advances in the understanding of the pathologic and molecular features of endometrial cancer have occurred since the FIGO staging was last updated in 2009. Substantially more outcome and biological behavior data are now available regarding the several histological types. Molecular and genetic findings have accelerated since the publication of The Cancer Genome Atlas (TCGA) data and provide improved clarity on the diverse biological nature of this collection of endometrial cancers and their differing prognostic outcomes. The goals of the new staging system are to better define these prognostic groups and create substages that indicate more appropriate surgical, radiation, and systemic therapies.INTRODUCTIONMany advances in the understanding of the pathologic and molecular features of endometrial cancer have occurred since the FIGO staging was last updated in 2009. Substantially more outcome and biological behavior data are now available regarding the several histological types. Molecular and genetic findings have accelerated since the publication of The Cancer Genome Atlas (TCGA) data and provide improved clarity on the diverse biological nature of this collection of endometrial cancers and their differing prognostic outcomes. The goals of the new staging system are to better define these prognostic groups and create substages that indicate more appropriate surgical, radiation, and systemic therapies.The FIGO Women's Cancer Committee appointed a Subcommittee on Endometrial Cancer Staging in October 2021, represented by the authors. Since then, the committee members have met frequently and reviewed new and established evidence on the treatment, prognosis, and survival of endometrial cancer. Based on these data, opportunities for improvements in the categorization and stratification of these factors were identified in each of the four stages. Data and analyses from the molecular and histological classifications performed and published in the recently developed ESGO/ESTRO/ESP guidelines were used as a template for adding the new subclassifications to the proposed molecular and histological staging system.METHODSThe FIGO Women's Cancer Committee appointed a Subcommittee on Endometrial Cancer Staging in October 2021, represented by the authors. Since then, the committee members have met frequently and reviewed new and established evidence on the treatment, prognosis, and survival of endometrial cancer. Based on these data, opportunities for improvements in the categorization and stratification of these factors were identified in each of the four stages. Data and analyses from the molecular and histological classifications performed and published in the recently developed ESGO/ESTRO/ESP guidelines were used as a template for adding the new subclassifications to the proposed molecular and histological staging system.Based on the existing evidence, the substages were defined as follows: Stage I (IA1): non-aggressive histological type of endometrial carcinoma limited to a polyp or confined to the endometrium; (IA2) non-aggressive histological types of endometrium involving less than 50% of the myometrium with no or focal lymphovascular space invasion (LVSI) as defined by WHO criteria; (IA3) low-grade endometrioid carcinomas limited to the uterus with simultaneous low-grade endometrioid ovarian involvement; (IB) non-aggressive histological types involving 50% or more of the myometrium with no LVSI or focal LVSI; (IC) aggressive histological types, i.e. serous, high-grade endometrioid, clear cell, carcinosarcomas, undifferentiated, mixed, and other unusual types without any myometrial invasion. Stage II (IIA): non-aggressive histological types that infiltrate the cervical stroma; (IIB) non-aggressive histological types that have substantial LVSI; or (IIC) aggressive histological types with any myometrial invasion. Stage III (IIIA): differentiating between adnexal versus uterine serosa infiltration; (IIIB) infiltration of vagina/parametria and pelvic peritoneal metastasis; and (IIIC) refinements for lymph node metastasis to pelvic and para-aortic lymph nodes, including micrometastasis and macrometastasis. Stage IV (IVA): locally advanced disease infiltrating the bladder or rectal mucosa; (IVB) extrapelvic peritoneal metastasis; and (IVC) distant metastasis. The performance of complete molecular classification (POLEmut, MMRd, NSMP, p53abn) is encouraged in all endometrial cancers. If the molecular subtype is known, this is recorded in the FIGO stage by the addition of "m" for molecular classification, and a subscript indicating the specific molecular subtype. When molecular classification reveals p53abn or POLEmut status in Stages I and II, this results in upstaging or downstaging of the disease (IICmp53abn or IAmPOLEmut).RESULTSBased on the existing evidence, the substages were defined as follows: Stage I (IA1): non-aggressive histological type of endometrial carcinoma limited to a polyp or confined to the endometrium; (IA2) non-aggressive histological types of endometrium involving less than 50% of the myometrium with no or focal lymphovascular space invasion (LVSI) as defined by WHO criteria; (IA3) low-grade endometrioid carcinomas limited to the uterus with simultaneous low-grade endometrioid ovarian involvement; (IB) non-aggressive histological types involving 50% or more of the myometrium with no LVSI or focal LVSI; (IC) aggressive histological types, i.e. serous, high-grade endometrioid, clear cell, carcinosarcomas, undifferentiated, mixed, and other unusual types without any myometrial invasion. Stage II (IIA): non-aggressive histological types that infiltrate the cervical stroma; (IIB) non-aggressive histological types that have substantial LVSI; or (IIC) aggressive histological types with any myometrial invasion. Stage III (IIIA): differentiating between adnexal versus uterine serosa infiltration; (IIIB) infiltration of vagina/parametria and pelvic peritoneal metastasis; and (IIIC) refinements for lymph node metastasis to pelvic and para-aortic lymph nodes, including micrometastasis and macrometastasis. Stage IV (IVA): locally advanced disease infiltrating the bladder or rectal mucosa; (IVB) extrapelvic peritoneal metastasis; and (IVC) distant metastasis. The performance of complete molecular classification (POLEmut, MMRd, NSMP, p53abn) is encouraged in all endometrial cancers. If the molecular subtype is known, this is recorded in the FIGO stage by the addition of "m" for molecular classification, and a subscript indicating the specific molecular subtype. When molecular classification reveals p53abn or POLEmut status in Stages I and II, this results in upstaging or downstaging of the disease (IICmp53abn or IAmPOLEmut).The updated 2023 staging of endometrial cancer includes the various histological types, tumor patterns, and molecular classification to better reflect the improved understanding of the complex nature of the several types of endometrial carcinoma and their underlying biologic behavior. The changes incorporated in the 2023 staging system should provide a more evidence-based context for treatment recommendations and for the more refined future collection of outcome and survival data.SUMMARYThe updated 2023 staging of endometrial cancer includes the various histological types, tumor patterns, and molecular classification to better reflect the improved understanding of the complex nature of the several types of endometrial carcinoma and their underlying biologic behavior. The changes incorporated in the 2023 staging system should provide a more evidence-based context for treatment recommendations and for the more refined future collection of outcome and survival data. |
| Author | Creutzberg, Carien Lindemann, Kristina Fotopoulou, Christina Kehoe, Sean Mutch, David Berek, Jonathan S. Matias-Guiu, Xavier Gaffney, David Concin, Nicole |
| AuthorAffiliation | 1 Stanford University School of Medicine, Stanford Women’s Cancer Center, Stanford Cancer Institute, Stanford, CA, USA 10 Kliniken Essen-Mitte, Essen, Germany 2 Department of Pathology, Hospital U de Bellvitge and Hospital U Arnau de Vilanova, Universities of Lleida and Barcelona, Institut de Recerca Biomèdica de Lleida, Instituto de Investigación Biomédica de Bellvitge, Centro de Investigación Biomédica en Red de Cáncer, Barcelona, Spain 9 Department of Obstetrics and Gynecology, Medical University of Innsbruck, Innsbruck, Austria 5 Department of Radiation Oncology, University of Utah, Salt Lake City, UT, USA 4 Gynaecological Oncology, Department of Surgery and Cancer, Imperial College London, London, UK 7 Department of Gynaecological Cancer, Oslo University Hospital, Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway 8 Division of Gynecologic Oncology, Washington University School of Medicine, St. Louis, MO, USA 6 Oxford Gynaecological Cancer Centre, Church |
| AuthorAffiliation_xml | – name: 2 Department of Pathology, Hospital U de Bellvitge and Hospital U Arnau de Vilanova, Universities of Lleida and Barcelona, Institut de Recerca Biomèdica de Lleida, Instituto de Investigación Biomédica de Bellvitge, Centro de Investigación Biomédica en Red de Cáncer, Barcelona, Spain – name: 1 Stanford University School of Medicine, Stanford Women’s Cancer Center, Stanford Cancer Institute, Stanford, CA, USA – name: 5 Department of Radiation Oncology, University of Utah, Salt Lake City, UT, USA – name: 4 Gynaecological Oncology, Department of Surgery and Cancer, Imperial College London, London, UK – name: 9 Department of Obstetrics and Gynecology, Medical University of Innsbruck, Innsbruck, Austria – name: 3 Department of Radiation Oncology, Leiden University Medical Center, Leiden, The Netherlands – name: 6 Oxford Gynaecological Cancer Centre, Churchill Hospital, Oxford, UK – name: 8 Division of Gynecologic Oncology, Washington University School of Medicine, St. Louis, MO, USA – name: 7 Department of Gynaecological Cancer, Oslo University Hospital, Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway – name: 10 Kliniken Essen-Mitte, Essen, Germany |
| Author_xml | – sequence: 1 givenname: Jonathan S. orcidid: 0000-0002-8734-1961 surname: Berek fullname: Berek, Jonathan S. organization: Stanford University School of Medicine, Stanford Women’s Cancer Center, Stanford Cancer Institute, Stanford, CA, USA – sequence: 2 givenname: Xavier orcidid: 0000-0002-7201-6605 surname: Matias-Guiu fullname: Matias-Guiu, Xavier organization: Department of Pathology, Hospital U de Bellvitge and Hospital U Arnau de Vilanova, Universities of Lleida and Barcelona, Institut de Recerca Biomèdica de Lleida, Instituto de Investigación Biomédica de Bellvitge, Centro de Investigación Biomédica en Red de Cáncer, Barcelona, Spain – sequence: 3 givenname: Carien orcidid: 0000-0002-7008-4321 surname: Creutzberg fullname: Creutzberg, Carien organization: Department of Radiation Oncology, Leiden University Medical Center, Leiden, The Netherlands – sequence: 4 givenname: Christina orcidid: 0000-0001-6375-9645 surname: Fotopoulou fullname: Fotopoulou, Christina organization: Gynaecological Oncology, Department of Surgery and Cancer, Imperial College London, London, UK – sequence: 5 givenname: David orcidid: 0000-0002-5752-1611 surname: Gaffney fullname: Gaffney, David organization: Department of Radiation Oncology, University of Utah, Salt Lake City, UT, USA – sequence: 6 givenname: Sean orcidid: 0000-0003-3830-9532 surname: Kehoe fullname: Kehoe, Sean organization: Oxford Gynaecological Cancer Centre, Churchill Hospital, Oxford, UK – sequence: 7 givenname: Kristina orcidid: 0000-0002-2162-0175 surname: Lindemann fullname: Lindemann, Kristina organization: Department of Gynaecological Cancer, Oslo University Hospital, Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway – sequence: 8 givenname: David orcidid: 0000-0002-6921-1581 surname: Mutch fullname: Mutch, David organization: Division of Gynecologic Oncology, Washington University School of Medicine, St. Louis, MO, USA – sequence: 9 givenname: Nicole orcidid: 0000-0002-9795-2643 surname: Concin fullname: Concin, Nicole organization: Department of Obstetrics and Gynecology, Medical University of Innsbruck, Innsbruck, Austria., Kliniken Essen-Mitte, Essen, Germany |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37593813$$D View this record in MEDLINE/PubMed https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002994720$$DAccess content in National Research Foundation of Korea (NRF) |
| BookMark | eNp1kUtLBDEQhIOs-D57kzkuwq6dx8wkXkTEx4IgiJ5DJpOs0dlEk1nBf2_GVVHBUzd01VfQtY1GPniD0D6GKeVAjh7nYUqA0CllU8PLNbRFAMoJUCFG3zuHTbSd0iNAVQMnG2iT1qWgHNMtNL6YXd4UqVdz5-dFsIXxbViYPjrVFVp5beJxMSTsonWrumT2PucOur84vzu7mlzfXM7OTq8nmhHRT1gD1jYcBKNtRYzGSjcNYC4EaYywSuOqhaalVd3WWBtmW0Ixpqa2SnANFd1Bhyuuj1Y-aSeDch9zHuRTlKe3dzOJgQKrqMjik5X4edksTKuN76Pq5HN0CxXfPqy_L949ZNBrJjBOSs4zYfxJiOFlaVIvFy5p03XKm7BMkvCSClZWZJAe_Az7Tvl6ZhaUK4GOIaVorNSuV70LQ7brcqgcSpO5NDm8VFImc2nZd_TH94X-z_EOmymX9w |
| CitedBy_id | crossref_primary_10_31083_CEOG39232 crossref_primary_10_2147_IJWH_S534822 crossref_primary_10_1159_000538268 crossref_primary_10_1002_mp_17768 crossref_primary_10_3390_medicina61030471 crossref_primary_10_3390_cancers16010185 crossref_primary_10_1007_s10565_024_09949_3 crossref_primary_10_3389_fonc_2024_1338908 crossref_primary_10_1186_s13014_023_02382_6 crossref_primary_10_1016_j_mri_2024_110298 crossref_primary_10_1016_j_gore_2024_101414 crossref_primary_10_3390_cancers16050921 crossref_primary_10_1016_j_gore_2025_101936 crossref_primary_10_1080_14789450_2023_2295861 crossref_primary_10_3802_jgo_2025_36_e93 crossref_primary_10_1016_j_ejogrb_2025_114679 crossref_primary_10_1159_000540357 crossref_primary_10_1007_s00428_023_03710_7 crossref_primary_10_1007_s10147_025_02697_2 crossref_primary_10_3802_jgo_2025_36_e123 crossref_primary_10_1016_j_prp_2024_155640 crossref_primary_10_1038_s41571_024_00934_7 crossref_primary_10_4103_jmh_jmh_191_24 crossref_primary_10_1186_s13244_025_01965_z crossref_primary_10_3390_ijms26188789 crossref_primary_10_1016_j_mri_2024_110283 crossref_primary_10_1016_j_ygyno_2024_08_015 crossref_primary_10_3389_fonc_2025_1652864 crossref_primary_10_1016_j_ejogrb_2023_10_008 crossref_primary_10_1097_PAS_0000000000002402 crossref_primary_10_1177_10668969241291878 crossref_primary_10_3389_fonc_2025_1510930 crossref_primary_10_1016_j_acra_2024_07_056 crossref_primary_10_1016_j_ygyno_2024_10_012 crossref_primary_10_1016_j_ejso_2024_108731 crossref_primary_10_1016_j_ygyno_2024_02_014 crossref_primary_10_1007_s00330_024_10861_x crossref_primary_10_1016_j_ejso_2025_109982 crossref_primary_10_25259_Cytojournal_37_2024 crossref_primary_10_1016_j_canrad_2024_10_002 crossref_primary_10_1007_s00262_024_03929_6 crossref_primary_10_3390_ijms25115893 crossref_primary_10_1002_ijc_35363 crossref_primary_10_1111_jog_16179 crossref_primary_10_1097_MD_0000000000036442 crossref_primary_10_1186_s12885_025_13424_5 crossref_primary_10_1136_bmjopen_2024_092006 crossref_primary_10_1016_j_humpath_2024_105704 crossref_primary_10_1186_s13244_025_01966_y crossref_primary_10_3390_diagnostics13243660 crossref_primary_10_1016_j_neo_2025_101229 crossref_primary_10_1016_j_gore_2024_101442 crossref_primary_10_1016_j_mri_2025_110324 crossref_primary_10_3390_medicina60091421 crossref_primary_10_3390_cells14171404 crossref_primary_10_1186_s12951_025_03516_6 crossref_primary_10_1111_his_15272 crossref_primary_10_3389_fonc_2023_1286221 crossref_primary_10_1016_j_ejrad_2025_112110 crossref_primary_10_62347_TUED9082 crossref_primary_10_3390_curroncol32050251 crossref_primary_10_1002_acn3_70068 crossref_primary_10_3390_ijms26062615 crossref_primary_10_1016_j_modpat_2025_100798 crossref_primary_10_1016_j_ijrobp_2025_05_004 crossref_primary_10_3390_cancers16050965 crossref_primary_10_3389_fonc_2025_1565152 crossref_primary_10_1016_j_ygyno_2025_05_001 crossref_primary_10_31083_j_ceog5010210 crossref_primary_10_1016_j_ygyno_2024_09_012 crossref_primary_10_3390_diagnostics14161735 crossref_primary_10_1016_j_prp_2025_156110 crossref_primary_10_1067_j_cpradiol_2024_08_009 crossref_primary_10_1016_j_acra_2023_12_035 crossref_primary_10_1177_15330338251345208 crossref_primary_10_1038_s41598_025_07379_7 crossref_primary_10_5114_pjr_189487 crossref_primary_10_1016_j_ejso_2024_108480 crossref_primary_10_2214_AJR_24_32157 crossref_primary_10_3390_cancers16051028 crossref_primary_10_3390_jcm14186484 crossref_primary_10_1186_s12905_024_03528_8 crossref_primary_10_1080_17520363_2024_2347192 crossref_primary_10_1007_s00261_025_04937_5 crossref_primary_10_1016_j_ygyno_2025_02_017 crossref_primary_10_1136_ijgc_2023_005173 crossref_primary_10_1136_bmj_2024_080978 crossref_primary_10_3390_diagnostics15172172 crossref_primary_10_1016_j_mpdhp_2024_06_003 crossref_primary_10_1016_j_ijgc_2025_102656 crossref_primary_10_1136_ijgc_2024_005769 crossref_primary_10_2147_IJWH_S506565 crossref_primary_10_1136_ijgc_2023_005201 crossref_primary_10_1186_s12957_024_03483_6 crossref_primary_10_1002_cncr_35267 crossref_primary_10_1007_s11864_025_01345_1 crossref_primary_10_1136_ijgc_2023_005181 crossref_primary_10_1007_s00262_024_03919_8 crossref_primary_10_1016_j_humpath_2025_105928 crossref_primary_10_3389_fonc_2024_1442489 crossref_primary_10_3390_life15071013 crossref_primary_10_1016_j_ygyno_2023_12_018 crossref_primary_10_1007_s00330_025_11700_3 crossref_primary_10_1038_s41598_025_12399_4 crossref_primary_10_3389_fonc_2025_1568137 crossref_primary_10_1016_j_ijgc_2025_101672 crossref_primary_10_3802_jgo_2026_37_e19 crossref_primary_10_1186_s12880_024_01391_5 |
| Cites_doi | 10.1097/IGC.0b013e3182a5055e 10.1038/modpathol.2015.127 10.1097/IGC.0000000000000490 10.1097/PGP.0000000000000524 10.1016/j.ijgo.2009.02.012 10.1097/IGC.0b013e3182954da8 10.1016/j.ygyno.2020.07.024 10.1016/S1470-2045(19)30395-X 10.1097/01.pas.0000180854.28831.77 10.1002/cncr.30496 10.1016/j.ygyno.2011.09.017 10.1097/PAS.0000000000001020 10.1097/PAS.0b013e3182073ac0 10.1126/science.aan6733 10.1007/s00404-019-05288-5 10.1016/j.humpath.2021.09.001 10.1186/s12957-019-1620-x 10.1097/PGP.0000000000000806 10.1002/path.5373 10.1097/PGP.0000000000000552 10.1111/his.14015 10.1056/NEJMoa2302312 10.1038/s41416-023-02141-0 10.1016/j.ygyno.2017.05.024 10.1002/1097-0142(19901015)60:8+<2035::AID-CNCR2820601515>3.0.CO;2-8 10.1016/j.ygyno.2017.09.027 10.7314/APJCP.2015.16.2.519 10.1038/bjc.2015.190 10.1056/NEJMoa2216334 10.1097/PGP.0000000000000805 10.1016/j.ygyno.2019.03.097 10.1097/PGP.0000000000000518 10.1016/j.jogoh.2022.102395 10.1016/j.modpat.2023.100212 10.1016/j.ygyno.2019.02.027 10.3802/jgo.2019.30.e7 10.1002/path.5372 10.1155/2011/962518 10.1097/PGP.0000000000000463 10.1016/j.ejca.2015.05.015 10.1111/j.1471-0528.2012.03427.x 10.1080/0284186X.2019.1643036 10.3802/jgo.2016.27.e1 10.1016/j.radonc.2020.11.018 10.1038/nature12113 10.1093/annonc/mdv484 10.1093/jnci/djv427 10.1016/j.ygyno.2020.03.025 10.1097/PAS.0b013e31820273dc 10.1097/IGC.0000000000001213 10.1200/JCO.20.00549 10.1002/jso.26102 10.1016/S1470-2045(12)70213-9 10.3802/jgo.2020.31.e58 10.1093/jnci/djv428 10.1046/j.1525-1438.1992.02010009.x 10.1038/modpathol.3800271 10.1016/j.ygyno.2018.10.033 10.1158/1078-0432.CCR-18-0266 10.1080/00313020601146814 10.3802/jgo.2021.32.e11 10.1097/PAP.0000000000000182 10.1016/j.humpath.2004.02.007 10.1097/IGC.0000000000000019 10.1245/s10434-015-5040-z 10.1136/ijgc-2022-003480 10.1111/his.13871 10.1016/j.ygyno.2008.09.009 10.1097/IGC.0b013e3182412ebd 10.3322/caac.21388 10.1007/s00428-020-03007-z 10.1136/ijgc-2020-002230 10.1016/j.ygyno.2003.08.003 10.1016/j.brachy.2020.12.006 10.1158/1078-0432.CCR-15-2878 10.1016/j.ygyno.2012.09.035 10.1016/j.ygyno.2016.12.015 10.1097/PGP.0000000000000415 |
| ContentType | Journal Article |
| Copyright | 2023. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology. 2023. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology 2023 Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology |
| Copyright_xml | – notice: 2023. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology. – notice: 2023. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology 2023 Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology |
| CorporateAuthor | Endometrial Cancer Staging Subcommittee, FIGO Women's Cancer Committee |
| CorporateAuthor_xml | – name: Endometrial Cancer Staging Subcommittee, FIGO Women's Cancer Committee |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM ACYCR |
| DOI | 10.3802/jgo.2023.34.e85 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) Korean Citation Index |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2005-0399 |
| EndPage | 18 |
| ExternalDocumentID | oai_kci_go_kr_ARTI_10304639 PMC10482588 37593813 10_3802_jgo_2023_34_e85 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | 29K 2WC 5-W 53G 5GY 8JR 8XY AAKDD AAYXX ABDBF ACUHS ADBBV AENEX ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL CITATION D-I DIK DU5 E3Z EBD EF. F5P GROUPED_DOAJ HYE HZB OK1 RPM 9ZL CGR CUY CVF ECM EIF NPM 7X8 5PM ACYCR M~E |
| ID | FETCH-LOGICAL-c429t-4b0ffb80943d62ec1acbb018992be9fac16d0bd367d71ce4fd23113e7fa98c063 |
| ISICitedReferencesCount | 122 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001080009100001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2005-0380 2005-0399 |
| IngestDate | Fri May 10 04:16:47 EDT 2024 Tue Nov 04 02:06:25 EST 2025 Wed Oct 01 14:32:57 EDT 2025 Thu Apr 03 07:10:56 EDT 2025 Tue Nov 18 21:53:09 EST 2025 Sat Nov 29 03:54:50 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Keywords | Endometrial Cancer FIGO Endometrial Cancer Staging FIGO Cancer Staging Cancer Staging Endometrial Cancer Molecular Staging |
| Language | English |
| License | 2023. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c429t-4b0ffb80943d62ec1acbb018992be9fac16d0bd367d71ce4fd23113e7fa98c063 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 https://doi.org/10.3802/jgo.2023.34.e85 |
| ORCID | 0000-0002-9795-2643 0000-0003-3830-9532 0000-0001-6375-9645 0000-0002-2162-0175 0000-0002-6921-1581 0000-0002-8734-1961 0000-0002-7008-4321 0000-0002-5752-1611 0000-0002-7201-6605 |
| OpenAccessLink | http://dx.doi.org/10.3802/jgo.2023.34.e85 |
| PMID | 37593813 |
| PQID | 2853945628 |
| PQPubID | 23479 |
| PageCount | 18 |
| ParticipantIDs | nrf_kci_oai_kci_go_kr_ARTI_10304639 pubmedcentral_primary_oai_pubmedcentral_nih_gov_10482588 proquest_miscellaneous_2853945628 pubmed_primary_37593813 crossref_citationtrail_10_3802_jgo_2023_34_e85 crossref_primary_10_3802_jgo_2023_34_e85 |
| PublicationCentury | 2000 |
| PublicationDate | 2023-09-01 |
| PublicationDateYYYYMMDD | 2023-09-01 |
| PublicationDate_xml | – month: 09 year: 2023 text: 2023-09-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Korea (South) |
| PublicationPlace_xml | – name: Korea (South) |
| PublicationTitle | Journal of gynecologic oncology |
| PublicationTitleAlternate | J Gynecol Oncol |
| PublicationYear | 2023 |
| Publisher | Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology; Japan Society of Gynecologic Oncology 대한부인종양학회 |
| Publisher_xml | – name: Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology; Japan Society of Gynecologic Oncology – name: 대한부인종양학회 |
| References | McCluggage (10.3802/jgo.2023.34.e85_ref18) 2018; 25 Church (10.3802/jgo.2023.34.e85_ref46) 2014; 107 Reijnen (10.3802/jgo.2023.34.e85_ref50) 2019; 154 Concin (10.3802/jgo.2023.34.e85_ref80) 2021; 154 Bosse (10.3802/jgo.2023.34.e85_ref1) 2018; 42 Matsuo (10.3802/jgo.2023.34.e85_ref64) 2017; 147 Stålberg (10.3802/jgo.2023.34.e85_ref67) 2019; 58 Peters (10.3802/jgo.2023.34.e85_ref17) 2019; 75 Anglesio (10.3802/jgo.2023.34.e85_ref29) 2016; 108 Bosse (10.3802/jgo.2023.34.e85_ref22) 2015; 51 Veade (10.3802/jgo.2023.34.e85_ref61) 2019; 17 de Boer (10.3802/jgo.2023.34.e85_ref70) 2019; 20 Colombo (10.3802/jgo.2023.34.e85_ref7) 2016; 27 Plante (10.3802/jgo.2023.34.e85_ref77) 2017; 146 Brierley (10.3802/jgo.2023.34.e85_ref2) 2016 Zaino (10.3802/jgo.2023.34.e85_ref26) 2013; 128 Zhan (10.3802/jgo.2023.34.e85_ref63) 2019; 300 Todo (10.3802/jgo.2023.34.e85_ref73) 2016; 27 Abeler (10.3802/jgo.2023.34.e85_ref8) 1992; 2 Peters (10.3802/jgo.2023.34.e85_ref66) 2022; 41 Lindauer (10.3802/jgo.2023.34.e85_ref12) 2003; 91 Ozbilen (10.3802/jgo.2023.34.e85_ref15) 2015; 16 Bogani (10.3802/jgo.2023.34.e85_ref76) 2019; 153 Van Gool (10.3802/jgo.2023.34.e85_ref48) 2018; 24 Chattopadhyay (10.3802/jgo.2023.34.e85_ref14) 2012; 119 Mirza (10.3802/jgo.2023.34.e85_ref51) 2023; 388 Talhouk (10.3802/jgo.2023.34.e85_ref42) 2017; 123 Rabban (10.3802/jgo.2023.34.e85_ref56) 2007; 39 Prat (10.3802/jgo.2023.34.e85_ref58) 2004; 35 Concin (10.3802/jgo.2023.34.e85_ref72) 2021; 31 Page (10.3802/jgo.2023.34.e85_ref71) 2012; 22 Hui (10.3802/jgo.2023.34.e85_ref55) 2005; 18 Eskander (10.3802/jgo.2023.34.e85_ref52) 2023; 388 Cancer Genome Atlas Research Network (10.3802/jgo.2023.34.e85_ref39) 2013; 497 dos Reis (10.3802/jgo.2023.34.e85_ref60) 2015; 25 Concin (10.3802/jgo.2023.34.e85_ref31) 2021; 478 Jamieson (10.3802/jgo.2023.34.e85_ref5) 2023; 36 Talhouk (10.3802/jgo.2023.34.e85_ref41) 2015; 113 Guntupalli (10.3802/jgo.2023.34.e85_ref69) 2012; 124 León-Castillo (10.3802/jgo.2023.34.e85_ref44) 2020; 250 Barnes (10.3802/jgo.2023.34.e85_ref23) 2021; 20 Burg (10.3802/jgo.2023.34.e85_ref78) 2020; 31 Xu (10.3802/jgo.2023.34.e85_ref57) 2022; 51 Betella (10.3802/jgo.2023.34.e85_ref81) 2022; 32 Schultheis (10.3802/jgo.2023.34.e85_ref30) 2016; 108 Kim (10.3802/jgo.2023.34.e85_ref37) 2013; 23 León-Castillo (10.3802/jgo.2023.34.e85_ref47) 2020; 250 Pifer (10.3802/jgo.2023.34.e85_ref20) 2020; 159 Malpica (10.3802/jgo.2023.34.e85_ref24) 2019; 38 St Clair (10.3802/jgo.2023.34.e85_ref75) 2016; 23 Assem (10.3802/jgo.2023.34.e85_ref54) 2021; 118 Mueller (10.3802/jgo.2023.34.e85_ref74) 2020; 157 Singh (10.3802/jgo.2023.34.e85_ref16) 2019; 38 Ouyang (10.3802/jgo.2023.34.e85_ref53) 2018; 28 León-Castillo (10.3802/jgo.2023.34.e85_ref38) 2020; 38 Vermij (10.3802/jgo.2023.34.e85_ref45) 2020; 76 Vermij (10.3802/jgo.2023.34.e85_ref6) 2023; 128 Euscher (10.3802/jgo.2023.34.e85_ref36) 2018; 37 Pecorelli (10.3802/jgo.2023.34.e85_ref9) 2009; 105 Jobsen (10.3802/jgo.2023.34.e85_ref27) 2011; 2011 Medeiros (10.3802/jgo.2023.34.e85_ref33) 2006; 30 Amin (10.3802/jgo.2023.34.e85_ref34) 2017; 67 Krizova (10.3802/jgo.2023.34.e85_ref21) 2011; 35 Salvesen (10.3802/jgo.2023.34.e85_ref59) 2012; 13 Peters (10.3802/jgo.2023.34.e85_ref68) 2022; 41 Li (10.3802/jgo.2023.34.e85_ref79) 2020; 122 McCluggage (10.3802/jgo.2023.34.e85_ref25) 2011; 35 Piulats (10.3802/jgo.2023.34.e85_ref40) 2017; 145 Barlin (10.3802/jgo.2023.34.e85_ref4) 2013; 23 Blakely (10.3802/jgo.2023.34.e85_ref35) 2019; 38 Schwab (10.3802/jgo.2023.34.e85_ref13) 2009; 112 Soslow (10.3802/jgo.2023.34.e85_ref10) 2019; 38 Stelloo (10.3802/jgo.2023.34.e85_ref43) 2016; 22 Tortorella (10.3802/jgo.2023.34.e85_ref62) 2021; 32 Heitz (10.3802/jgo.2023.34.e85_ref28) 2014; 24 Le (10.3802/jgo.2023.34.e85_ref49) 2017; 357 Yoneoka (10.3802/jgo.2023.34.e85_ref65) 2019; 30 WHO Classification of Tumours Editorial Board (10.3802/jgo.2023.34.e85_ref3) 2020 Soslow (10.3802/jgo.2023.34.e85_ref19) 2016; 29 Turashvili (10.3802/jgo.2023.34.e85_ref32) 2019; 152 Creasman (10.3802/jgo.2023.34.e85_ref11) 1987; 60 37832479 - Eur J Obstet Gynecol Reprod Biol. 2023 Dec;291:59-60 |
| References_xml | – volume: 23 start-page: 1620 year: 2013 ident: 10.3802/jgo.2023.34.e85_ref4 publication-title: Int J Gynecol Cancer doi: 10.1097/IGC.0b013e3182a5055e – volume: 29 start-page: S59 issue: Suppl 1 year: 2016 ident: 10.3802/jgo.2023.34.e85_ref19 publication-title: Mod Pathol doi: 10.1038/modpathol.2015.127 – volume: 25 start-page: 1292 year: 2015 ident: 10.3802/jgo.2023.34.e85_ref60 publication-title: Int J Gynecol Cancer doi: 10.1097/IGC.0000000000000490 – volume: 38 start-page: S93 issue: Suppl 1 year: 2019 ident: 10.3802/jgo.2023.34.e85_ref16 publication-title: Int J Gynecol Pathol doi: 10.1097/PGP.0000000000000524 – volume: 105 start-page: 103 year: 2009 ident: 10.3802/jgo.2023.34.e85_ref9 publication-title: Int J Gynaecol Obstet doi: 10.1016/j.ijgo.2009.02.012 – volume: 23 start-page: 964 year: 2013 ident: 10.3802/jgo.2023.34.e85_ref37 publication-title: Int J Gynecol Cancer doi: 10.1097/IGC.0b013e3182954da8 – volume: 159 start-page: 23 year: 2020 ident: 10.3802/jgo.2023.34.e85_ref20 publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2020.07.024 – volume: 20 start-page: 1273 year: 2019 ident: 10.3802/jgo.2023.34.e85_ref70 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(19)30395-X – volume: 30 start-page: 230 year: 2006 ident: 10.3802/jgo.2023.34.e85_ref33 publication-title: Am J Surg Pathol doi: 10.1097/01.pas.0000180854.28831.77 – volume: 123 start-page: 802 year: 2017 ident: 10.3802/jgo.2023.34.e85_ref42 publication-title: Cancer doi: 10.1002/cncr.30496 – volume: 124 start-page: 31 year: 2012 ident: 10.3802/jgo.2023.34.e85_ref69 publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2011.09.017 – volume: 42 start-page: 561 year: 2018 ident: 10.3802/jgo.2023.34.e85_ref1 publication-title: Am J Surg Pathol doi: 10.1097/PAS.0000000000001020 – volume: 35 start-page: 289 year: 2011 ident: 10.3802/jgo.2023.34.e85_ref25 publication-title: Am J Surg Pathol doi: 10.1097/PAS.0b013e3182073ac0 – volume: 357 start-page: 409 year: 2017 ident: 10.3802/jgo.2023.34.e85_ref49 publication-title: Science doi: 10.1126/science.aan6733 – volume: 300 start-page: 1045 year: 2019 ident: 10.3802/jgo.2023.34.e85_ref63 publication-title: Arch Gynecol Obstet doi: 10.1007/s00404-019-05288-5 – volume: 118 start-page: 1 year: 2021 ident: 10.3802/jgo.2023.34.e85_ref54 publication-title: Hum Pathol doi: 10.1016/j.humpath.2021.09.001 – volume: 17 start-page: 80 year: 2019 ident: 10.3802/jgo.2023.34.e85_ref61 publication-title: World J Surg Oncol doi: 10.1186/s12957-019-1620-x – volume: 41 start-page: 220 year: 2022 ident: 10.3802/jgo.2023.34.e85_ref66 publication-title: Int J Gynecol Pathol doi: 10.1097/PGP.0000000000000806 – volume: 250 start-page: 312 year: 2020 ident: 10.3802/jgo.2023.34.e85_ref44 publication-title: J Pathol doi: 10.1002/path.5373 – volume: 38 start-page: S9 issue: Suppl 1 year: 2019 ident: 10.3802/jgo.2023.34.e85_ref24 publication-title: Int J Gynecol Pathol doi: 10.1097/PGP.0000000000000552 – volume: 76 start-page: 52 year: 2020 ident: 10.3802/jgo.2023.34.e85_ref45 publication-title: Histopathology doi: 10.1111/his.14015 – volume: 388 start-page: 2159 year: 2023 ident: 10.3802/jgo.2023.34.e85_ref52 publication-title: N Engl J Med doi: 10.1056/NEJMoa2302312 – volume: 128 start-page: 1360 year: 2023 ident: 10.3802/jgo.2023.34.e85_ref6 publication-title: Br J Cancer doi: 10.1038/s41416-023-02141-0 – volume: 146 start-page: 240 year: 2017 ident: 10.3802/jgo.2023.34.e85_ref77 publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2017.05.024 – volume: 60 start-page: 2035 year: 1987 ident: 10.3802/jgo.2023.34.e85_ref11 publication-title: Cancer doi: 10.1002/1097-0142(19901015)60:8+<2035::AID-CNCR2820601515>3.0.CO;2-8 – volume: 147 start-page: 558 year: 2017 ident: 10.3802/jgo.2023.34.e85_ref64 publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2017.09.027 – volume: 16 start-page: 519 year: 2015 ident: 10.3802/jgo.2023.34.e85_ref15 publication-title: Asian Pac J Cancer Prev doi: 10.7314/APJCP.2015.16.2.519 – volume: 113 start-page: 299 year: 2015 ident: 10.3802/jgo.2023.34.e85_ref41 publication-title: Br J Cancer doi: 10.1038/bjc.2015.190 – volume: 388 start-page: 2145 year: 2023 ident: 10.3802/jgo.2023.34.e85_ref51 publication-title: N Engl J Med doi: 10.1056/NEJMoa2216334 – volume: 41 start-page: 227 year: 2022 ident: 10.3802/jgo.2023.34.e85_ref68 publication-title: Int J Gynecol Pathol doi: 10.1097/PGP.0000000000000805 – volume: 154 start-page: 124 year: 2019 ident: 10.3802/jgo.2023.34.e85_ref50 publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2019.03.097 – volume: 38 start-page: S64 issue: Suppl 1 year: 2019 ident: 10.3802/jgo.2023.34.e85_ref10 publication-title: Int J Gynecol Pathol doi: 10.1097/PGP.0000000000000518 – volume: 51 start-page: 102395 year: 2022 ident: 10.3802/jgo.2023.34.e85_ref57 publication-title: J Gynecol Obstet Hum Reprod doi: 10.1016/j.jogoh.2022.102395 – volume: 36 start-page: 100212 year: 2023 ident: 10.3802/jgo.2023.34.e85_ref5 publication-title: Mod Pathol doi: 10.1016/j.modpat.2023.100212 – volume: 153 start-page: 670 year: 2019 ident: 10.3802/jgo.2023.34.e85_ref76 publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2019.02.027 – start-page: 131 volume-title: TNM classification of malignant tumours year: 2016 ident: 10.3802/jgo.2023.34.e85_ref2 – volume: 30 start-page: e7 year: 2019 ident: 10.3802/jgo.2023.34.e85_ref65 publication-title: J Gynecol Oncol doi: 10.3802/jgo.2019.30.e7 – volume-title: Female genital tumours, WHO classification of tumours. Vol. 4 year: 2020 ident: 10.3802/jgo.2023.34.e85_ref3 – volume: 250 start-page: 323 year: 2020 ident: 10.3802/jgo.2023.34.e85_ref47 publication-title: J Pathol doi: 10.1002/path.5372 – volume: 2011 start-page: 962518 year: 2011 ident: 10.3802/jgo.2023.34.e85_ref27 publication-title: Obstet Gynecol Int doi: 10.1155/2011/962518 – volume: 38 start-page: 52 year: 2019 ident: 10.3802/jgo.2023.34.e85_ref35 publication-title: Int J Gynecol Pathol doi: 10.1097/PGP.0000000000000463 – volume: 51 start-page: 1742 year: 2015 ident: 10.3802/jgo.2023.34.e85_ref22 publication-title: Eur J Cancer doi: 10.1016/j.ejca.2015.05.015 – volume: 119 start-page: 1162 year: 2012 ident: 10.3802/jgo.2023.34.e85_ref14 publication-title: BJOG doi: 10.1111/j.1471-0528.2012.03427.x – volume: 58 start-page: 1628 year: 2019 ident: 10.3802/jgo.2023.34.e85_ref67 publication-title: Acta Oncol doi: 10.1080/0284186X.2019.1643036 – volume: 107 start-page: 402 year: 2014 ident: 10.3802/jgo.2023.34.e85_ref46 publication-title: J Natl Cancer Inst – volume: 27 start-page: e1 year: 2016 ident: 10.3802/jgo.2023.34.e85_ref73 publication-title: J Gynecol Oncol doi: 10.3802/jgo.2016.27.e1 – volume: 154 start-page: 327 year: 2021 ident: 10.3802/jgo.2023.34.e85_ref80 publication-title: Radiother Oncol doi: 10.1016/j.radonc.2020.11.018 – volume: 497 start-page: 67 year: 2013 ident: 10.3802/jgo.2023.34.e85_ref39 publication-title: Nature doi: 10.1038/nature12113 – volume: 27 start-page: 16 year: 2016 ident: 10.3802/jgo.2023.34.e85_ref7 publication-title: Ann Oncol doi: 10.1093/annonc/mdv484 – volume: 108 start-page: djv427 year: 2016 ident: 10.3802/jgo.2023.34.e85_ref30 publication-title: J Natl Cancer Inst doi: 10.1093/jnci/djv427 – volume: 157 start-page: 619 year: 2020 ident: 10.3802/jgo.2023.34.e85_ref74 publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2020.03.025 – volume: 35 start-page: 115 year: 2011 ident: 10.3802/jgo.2023.34.e85_ref21 publication-title: Am J Surg Pathol doi: 10.1097/PAS.0b013e31820273dc – volume: 28 start-page: 524 year: 2018 ident: 10.3802/jgo.2023.34.e85_ref53 publication-title: Int J Gynecol Cancer doi: 10.1097/IGC.0000000000001213 – volume: 38 start-page: 3388 year: 2020 ident: 10.3802/jgo.2023.34.e85_ref38 publication-title: J Clin Oncol doi: 10.1200/JCO.20.00549 – volume: 122 start-page: 941 year: 2020 ident: 10.3802/jgo.2023.34.e85_ref79 publication-title: J Surg Oncol doi: 10.1002/jso.26102 – volume: 13 start-page: e353 year: 2012 ident: 10.3802/jgo.2023.34.e85_ref59 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(12)70213-9 – volume: 31 start-page: e58 year: 2020 ident: 10.3802/jgo.2023.34.e85_ref78 publication-title: J Gynecol Oncol doi: 10.3802/jgo.2020.31.e58 – volume: 108 start-page: djv428 year: 2016 ident: 10.3802/jgo.2023.34.e85_ref29 publication-title: J Natl Cancer Inst doi: 10.1093/jnci/djv428 – volume: 2 start-page: 9 year: 1992 ident: 10.3802/jgo.2023.34.e85_ref8 publication-title: Int J Gynecol Cancer doi: 10.1046/j.1525-1438.1992.02010009.x – volume: 18 start-page: 75 year: 2005 ident: 10.3802/jgo.2023.34.e85_ref55 publication-title: Mod Pathol doi: 10.1038/modpathol.3800271 – volume: 152 start-page: 38 year: 2019 ident: 10.3802/jgo.2023.34.e85_ref32 publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2018.10.033 – volume: 24 start-page: 3197 year: 2018 ident: 10.3802/jgo.2023.34.e85_ref48 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-18-0266 – volume: 39 start-page: 125 year: 2007 ident: 10.3802/jgo.2023.34.e85_ref56 publication-title: Pathology doi: 10.1080/00313020601146814 – volume: 32 start-page: e11 year: 2021 ident: 10.3802/jgo.2023.34.e85_ref62 publication-title: J Gynecol Oncol doi: 10.3802/jgo.2021.32.e11 – volume: 25 start-page: 71 year: 2018 ident: 10.3802/jgo.2023.34.e85_ref18 publication-title: Adv Anat Pathol doi: 10.1097/PAP.0000000000000182 – volume: 35 start-page: 649 year: 2004 ident: 10.3802/jgo.2023.34.e85_ref58 publication-title: Hum Pathol doi: 10.1016/j.humpath.2004.02.007 – volume: 24 start-page: 54 year: 2014 ident: 10.3802/jgo.2023.34.e85_ref28 publication-title: Int J Gynecol Cancer doi: 10.1097/IGC.0000000000000019 – volume: 23 start-page: 1653 year: 2016 ident: 10.3802/jgo.2023.34.e85_ref75 publication-title: Ann Surg Oncol doi: 10.1245/s10434-015-5040-z – volume: 32 start-page: 993 year: 2022 ident: 10.3802/jgo.2023.34.e85_ref81 publication-title: Int J Gynecol Cancer doi: 10.1136/ijgc-2022-003480 – volume: 75 start-page: 128 year: 2019 ident: 10.3802/jgo.2023.34.e85_ref17 publication-title: Histopathology doi: 10.1111/his.13871 – volume: 112 start-page: 146 year: 2009 ident: 10.3802/jgo.2023.34.e85_ref13 publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2008.09.009 – volume: 22 start-page: 593 year: 2012 ident: 10.3802/jgo.2023.34.e85_ref71 publication-title: Int J Gynecol Cancer doi: 10.1097/IGC.0b013e3182412ebd – volume: 67 start-page: 93 year: 2017 ident: 10.3802/jgo.2023.34.e85_ref34 publication-title: CA Cancer J Clin doi: 10.3322/caac.21388 – volume: 478 start-page: 153 year: 2021 ident: 10.3802/jgo.2023.34.e85_ref31 publication-title: Virchows Arch doi: 10.1007/s00428-020-03007-z – volume: 31 start-page: 12 year: 2021 ident: 10.3802/jgo.2023.34.e85_ref72 publication-title: Int J Gynecol Cancer doi: 10.1136/ijgc-2020-002230 – volume: 91 start-page: 547 year: 2003 ident: 10.3802/jgo.2023.34.e85_ref12 publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2003.08.003 – volume: 20 start-page: 527 year: 2021 ident: 10.3802/jgo.2023.34.e85_ref23 publication-title: Brachytherapy doi: 10.1016/j.brachy.2020.12.006 – volume: 22 start-page: 4215 year: 2016 ident: 10.3802/jgo.2023.34.e85_ref43 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-15-2878 – volume: 128 start-page: 83 year: 2013 ident: 10.3802/jgo.2023.34.e85_ref26 publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2012.09.035 – volume: 145 start-page: 200 year: 2017 ident: 10.3802/jgo.2023.34.e85_ref40 publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2016.12.015 – volume: 37 start-page: 242 year: 2018 ident: 10.3802/jgo.2023.34.e85_ref36 publication-title: Int J Gynecol Pathol doi: 10.1097/PGP.0000000000000415 – reference: 37832479 - Eur J Obstet Gynecol Reprod Biol. 2023 Dec;291:59-60 |
| SSID | ssj0067082 |
| Score | 2.6121545 |
| Snippet | Many advances in the understanding of the pathologic and molecular features of endometrial cancer have occurred since the FIGO staging was last updated in... Introduction: Many advances in the understanding of the pathologic and molecular features of endometrial cancer have occurred since the FIGO staging was last... |
| SourceID | nrf pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | e85 |
| SubjectTerms | Carcinoma, Endometrioid Endometrial Neoplasms - genetics Endometrium Female FIGO Staging Update Humans Peritoneal Neoplasms Uterus 산부인과학 |
| Title | FIGO staging of endometrial cancer: 2023 |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/37593813 https://www.proquest.com/docview/2853945628 https://pubmed.ncbi.nlm.nih.gov/PMC10482588 https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002994720 |
| Volume | 34 |
| WOSCitedRecordID | wos001080009100001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | Journal of Gynecologic Oncology, 2023, 34(5), , pp.1-18 |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2005-0399 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0067082 issn: 2005-0380 databaseCode: DOA dateStart: 20110101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELfagRAviG_KxxQEkSZV6ZI4HzZvbdeOSWwgMaS-RY7jlLKSVGkyDf4v_j_OcZI2FUPjgZfIurrJ9X7X851zvkPorekwAgufbTAcMcMBj8Ogti8MEcXEBYtIaVwi_cE_OyOzGf3U6fyqz8JcLv0kIVdXdPVfoQYagC2Pzv4D3M1NgQBjAB2uADtcbwT89OT4o9whmFf5zCKJ0u9CdefgEuOyMaTsZ36NYzr_kQiubGI_TXhr373ebO9_HvRHIhPNOZ8ZK8-tnAITbG0cF4ti83ZDllLujzNR5D-bglp1gd98kbD-NM3TVVos02J7E8LGTZaVUht9MtLJWOZmTI506up0LCkjr6SMdXqkj4gcDG2duCXF06lVT6blYAh32Bi_skKqiVWXp4HYpqmGSpXBtbZWbmXId9cEuIesMfttLo962niAnYFQXYLa1bd3VsVW_e0LvgjmaXCRBRBlnASWKrRGu-iW7buU1pG8cgA83yx7lDU_QVWUknwc7nDRcoa6SRb_Kc7ZTdfd8n_O76N7lX5oQ6VwD1BHJA_RndMqNeMROpB6p1V6p6WxtqV3mtK7d5pk6jH6Mp2cj98bVRsOg4OzkhtOaMZxSGQKauTZgluMh6FpQaBuh4LGjFteZIYR9vzIt7hw4ghiBgsLP2aUcHCBn6C9JE3EM6RhiI4F9rlnRZYjWMiY8ELbY3HEIxO7uIcGtTwCXtWol61SliDyQAowAAEGktcAOwEIsIcOmi-sVHmW66e-AQGXUP4F0h56XQMQgKGVb89YItJiHdjg2FK5X0B66KkCpHkkBi0A1xf4Jy2omgnyie1PksXXspi7BUuo7RLy_EbsvUB3N3-_l2gvzwrxCt3ml_line2jrj8j-6Uy_gYU9rJx |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=FIGO+staging+of+endometrial+cancer%3A+2023&rft.jtitle=Journal+of+gynecologic+oncology&rft.au=Jonathan+S.+Berek&rft.au=Xavier+Matias-Guiu&rft.au=Carien+Creutzberg&rft.au=Christina+Fotopoulou&rft.date=2023-09-01&rft.pub=%EB%8C%80%ED%95%9C%EB%B6%80%EC%9D%B8%EC%A2%85%EC%96%91%ED%95%99%ED%9A%8C&rft.issn=2005-0380&rft.eissn=2005-0399&rft.spage=1&rft.epage=18&rft_id=info:doi/10.3802%2Fjgo.2023.34.e85&rft.externalDBID=n%2Fa&rft.externalDocID=oai_kci_go_kr_ARTI_10304639 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2005-0380&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2005-0380&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2005-0380&client=summon |